UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 20-F/A

(Amendment No. 1)

 

 

 

(Mark One)

 

[  ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2016

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

[  ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report: Not applicable

For the transition period from ____________ to ____________

Commission file number 001-36581

 

 

Vascular Biogenics Ltd.

(Exact name of registrant as specified in its charter)

 

 

N/A

(Translation of Registrant’s name into English)

 

Israel

(Jurisdiction of incorporation or organization)

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

(Address of principal executive offices)

Dror Harats, Chief Executive Officer

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

Tel: +972 3 634 6450

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

Title of Each Class   Name of Each Exchange on which Registered
Ordinary Shares, par value NIS 0.01 each   The NASDAQ Stock Market LLC

 

Securities registered or to be registered pursuant to Section 12(g) of the Act. None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None

 

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

 

As of December 31, 2016, the Registrant had 26,902,285 Ordinary Shares outstanding.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [  ] No [X]

 

If this report is an annual report or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes [  ] No [X]

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [X]   Non-accelerated filer [  ]
        Emerging growth company [X]

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP [  ]  

International Financing Reporting Standards as issued

by the International Accounting Standards Board [X]

  Other [  ]

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 [  ] Item 18 [  ]

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

 

 

 

 

 

Explanatory Note

 

Vascular Biogenics Ltd. (“the Company”) is filing this Amendment No. 1 to its Annual Report on Form 20-F for the year ended December 31, 2016 (the “Annual Report”), which was originally filed with the Securities and Exchange Commission on March 27, 2017, solely to include the correct version of Exhibit 4.3, as the Annual Report inadvertently included a draft version of the document as Exhibit 4.3. There are no other changes to the Annual Report. Therefore, this Amendment No. 1 consists of a cover page, this explanatory note, a revised list of exhibits (Item 19 of Part III), a signature page and related certifications as Exhibits 12.1 and 12.2.

 

This Amendment No. 1 speaks as of the date of the original filing of the Annual Report, and the Company has not updated the disclosures contained therein to reflect any events that occurred at a later date.

 

 

 

 

Item 19. Exhibits

 

Exhibit No.   Description
     
1.1   Articles of Association of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on September 30, 2014).
     
1.2   Memorandum of Association of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.4 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on September 30, 2014).
     
2.1   Amended and Restated Investors’ Rights Agreement, dated as of March 13, 2008, by and among the Registrant and the other parties thereto, as amended. (incorporated by reference to Exhibit 4.1 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
2.2   Form of Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.2 of Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 29, 2014).
     
2.3   Warrant to purchase ordinary shares, dated May 8, 2014, issued to S.R. Horn Assets Ltd. (incorporated by reference to Exhibit 4.3 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
2.4   Warrant to purchase ordinary shares, dated April 1, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.4 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
2.5   Warrant to purchase ordinary shares, dated May 14, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.5 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
2.6   Warrant to purchase ordinary shares, dated December 28, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.6 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
4.1   Employee Ownership and Share Option Plan (2011) of the Registrant, and form of agreement thereunder (incorporated by reference to Exhibit 10.1 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
4.2   Form of Release and Indemnification Agreement to be entered into between the Registrant and its officers and directors (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 25, 2014).
     
4.3†*   Commercial Gene Therapy License Agreement, dated April 15, 2011, between the Registrant and Crucell Holland B.V.
     
4.4†   Agreement, dated February 3, 2013, between the Registrant and Tel Hashomer—Medical Research, Infrastructure and Services Ltd. (incorporated by reference to Exhibit 10.4 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.5†   Manufacturing Services Agreement, dated January 5, 2012, between the Registrant and Lonza Houston, Inc. (incorporated by reference to Exhibit 10.5 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.6   Master Services Agreement, dated May 14, 2008, between the Registrant and Genzyme Pharmaceuticals (incorporated by reference to Exhibit 10.6 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).

 

 -i-
  

 

4.7†   Technical Agreement on the Manufacture of Capsules, dated April 29, 2008, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order (incorporated by reference to Exhibit 10.7 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.8†   Technical Agreement on the Manufacture of Capsules, dated August 3, 2012, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order (incorporated by reference to Exhibit 10.8 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.9†   Material Transfer and Confidentiality Agreement, effective as of September 19, 2005, among the Registrant, Crucell Holland B.V. and BioReliance Ltd. (incorporated by reference to Exhibit 10.9 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.10†   General Services Agreement, dated September 24, 2012, between the Registrant and BioClinica, Inc., and Addendum dated November 19, 2012 and August 29, 2013 (incorporated by reference to Exhibit 10.10 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.11†   Clinical Trial Agreement, dated September 9, 2012, between the Registrant and SCIderm GmbH (incorporated by reference to Exhibit 10.11 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.12†   Service Agreement, dated November 8, 2012, between the Registrant and KCR S.A. (incorporated by reference to Exhibit 10.12 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.13†   Service Agreement, dated December 16, 2013, between the Registrant and KCR S.A. (incorporated by reference to Exhibit 10.13 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.14#   Lease Agreement, dated January 2013, between the Registrant and Matzlawi Building Company Ltd. (incorporated by reference to Exhibit 10.14 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
4.15†   Material Transfer and Confidentiality Agreement, effective February 6, 2012 between the Registrant, Crucell Holland B.V. and Lonza Houston, Inc. (incorporated by reference to Exhibit 10.15 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July 18, 2014).
     
4.16   Agreement between the Registrant and Prof. Jacob George, dated January 24, 2010, as amended on August 1, 2012 (incorporated by reference to Exhibit 10.16 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 6, 2014).
     
4.17   Employee Share Ownership and Option Plan (2014) of the Registrant, and form of Capital Gains Option Agreement thereunder (incorporated by reference to Exhibit 10.17 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on June 25, 2014).
     
4.18†   Master Services Agreement, effective as of January 30, 2015, by and between PPD Development, L.P. and the Registrant.

 

4.19#   Lease Agreement, dated as of June 10, 2016, by and between the Registrant and Darwish Shalom (incorporated by reference to Exhibit 4.19 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2017).
     
12.1*   Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).
     
12.2*   Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).
     
13.1   Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 13.1 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2017).
     
15.1   Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, Independent Registered Public Accounting Firm (incorporated by reference to Exhibit 15.1 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2017).

 

 

Portions of this exhibit have been omitted pursuant to a grant of confidential treatment by the Securities and Exchange Commission and the non-public information has been filed separately with the Securities and Exchange Commission.
# English summary of original Hebrew document.
* Filed herewith

 

 

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

VASCULAR BIOGENICS LTD.  
     
By: /s/ Dror Harats  
 

Dror Harats

 
  Chief Executive Officer  

 

Date: October 11, 2017

 

 

 

 

 

Exhibit 4.3

 

CRUCELL HOLLAND B.V. – VASCULAR BIO GENICS LTD.

 

COMMERCIAL GENE THERAPY LICENSE AGREEMENT

 

 1
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

COMMERCIAL GENE THERAPY LICENSE AGREEMENT

 

This Commercial Gene Therapy License Agreement (“Agreement”) is made and entered into on April 15, 2011 (“EFFECTIVE DATE”) by and between:

 

CRUCELL HOLLAND B.V., a corporation organized under the laws of the Netherlands, having offices located at Archimedesweg 4, 2333 CN, Leiden, the Netherlands “CRUCELL”)

 

and

 

VASCULAR BIOGENICS Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter referred to as “VBL” or “LICENSEE”),

 

the parties hereinafter individually referred to as “Party” and collectively as “Parties”.

 

PREAMBLE

 

WHEREAS, CRUCELL is the owner of a PER.C6® cell line and of the associated information, know-how, and patents rights (as defined below);
   
WHEREAS, LICENSEE is engaged in the business of biomedical research, and the manufacturing, testing and commercializing of pharmaceutical products and services;
   
WHEREAS, LICENSEE and CRUCELL are parties to a Research License and Option Agreement dated March 24, 2005, granting LICENSEE the rights to conduct research under the PER.C6® PATENTS and to utilize PER.C6® KNOW HOW (as such terms are defined below) to prepare and evaluate gene therapeutics based on adenoviral vectors, and an option for a commercial license;
   
WHEREAS, LICENSEE has exercised its option to a commercial license and the Parties have negotiated an agreement for commercial rights under the terms and conditions as set forth hereinafter;

 

NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein, the Parties, intending to be legally bound, agree as follows:

 

1. DEFINITIONS

 

Plural used in this Agreement shall mean singular and vice versa.

 

  1.1 AFFILIATE means any corporation, organization or other legal entity which, directly or indirectly, controls, or is controlled by, or is under common control with, a Party. CONTROL shall mean the ability, directly or indirectly, to direct the activities of the relevant entity, including the ownership or holding (directly or indirectly) of fifty percent (50%) or more of (i) the securities or other ownership interests representing the equity, the voting stock or general partnership interest, or (ii) the rights to elect or appoint directors (or other governing body).
     
  1.2 APPROVED COUNTRIES means the countries mentioned in Exhibit 1.2
     
  1.3 BMF means the PER.C6® Biologies Master File as filed with the United States Food and Drug Administration
     
  1.4 EFFECTIVE DATE has the meaning set forth in the first paragraph of this Agreement.

 

 2
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics 

 

  1.5 FIELD means the treatment of cancer in human by administering to a subject an adenoviral vector including, but not limited to, therapeutic gene sequence(s), the therapeutic effect of which is principally caused by the expression product of said gene sequence(s) and will not serve as a vaccine.
  1.6 FIRST COMMERCIAL SALE means the first sale of a PRODUCT in a country by LICENSEE or any of its SUBLICENSEES OR REGISTERED AFFILIATES.
     
  1.7 FUNCTIONAL GENOMICS means the identification and/or validation of the biological function(s) of human and animal genes, and/or gene fragments and/or proteins and/or fragments of proteins transcribed from such genes, by means of the construction and use of arrayed collections of said genes and/or gene fragments, in non-phage viral vectors, to enable the identification and validation of drug targets, nutriceuticals and/or protein therapeutics, for the treatment or prevention of human or animal disease(s) and/or the maintenance of nutritional health.
     
  1.8 GOVERNMENTAL AUTHORITIES means the FDA and other foreign governmental equivalents.
     
  1.9 IMPROVEMENT KNOW HOW RIGHTS means know how rights owned or licensable by LICENSEE or its REGISTERED AFFILIATES, which are developed during the TERM using the technology claimed by the IMPROVEMENT PATENT RIGHTS, and which (i) come into the possession of LICENSEE or its REGISTERED AFFILIATES during the course of PROGRAMS and during the TERM of this Agreement, (ii) are not generally known, (iii) are related to the subject matter(s) of the IMPROVEMENT PATENT RIGHTS and are necessary for CRUCELL’s practice of the IMPROVEMENT PATENT RIGHTS as permitted under Section 2.5, and (iv) are not subject to a good faith reasonable third party confidentiality obligation that prevents the disclosure of the same.
     
  1.10 IMPROVEMENT PATENT RIGHTS means any patent issued after the EFFECTIVE DATE only to the extent that it claims (i) a new use of the PACKAGING CELLS including a generic product by process using said cells, (ii) an improved cell line derived from the PACKAGING CELLS, (iii) culturing or processing of PACKAGING CELLS, or (iv) a new use of an improved cell line described in clause (ii) of this sentence, in each case that is developed during the course of PROGRAMS under this Agreement.
     
  1.11 MODIFIED CELLS means PER.C6® CELLS modified by incorporating therein VBL TECHNOLOGY, but excluding the integration thereof into the genome of the PER.C6® CELL.
     
  1.12 NET SALES means the gross amount invoiced on sales of the PRODUCTS by LICENSEE, SUBLICENSEES, REGISTERED AFFILIATES and/or their respective sub-licensees to third party customers, less the following deductions related to the sale and delivery of PRODUCTS: (i) any commercially reasonable credits and allowances, repayments, refunds, or adjustments granted or made to customers; (ii) any commercially reasonable trade or cash discounts, rebates, charge-backs or administrative fees or other price reductions granted to customers; (iii) any sales, transportation, import, export or other like taxes, duties and government charges (but specifically excluding any taxes based on net income imposed upon the sale of the PRODUCTS) to the extent included in the gross sales price; (iv) the actual amount of any write-offs for uncollectible invoices; and (v) transportation costs, including insurance and shipping, freight and handling charges, wherein rebates, charge-backs, administrative fees and, or other like taxes are actually paid or incurred by LICENSEE, SUBLICENSEES, REGISTERED AFFILIATES and/or their respective sub-licensees. A sale of the Product to third party customers shall also include a transfer or other disposition for consideration other than cash, in which case such consideration shall be valued at the fair market value thereof.

 

 3
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics 

 

  1.13 NON-APPROVED COUNTRIES means any countries other than APPROVED COUNTRIES.
     
  1.14 PACKAGING CELLS means PER.C6® CELLS and MODIFIED CELLS.
     
  1.15 PACKAGING CELL-EXPRESSION SEQUENCE means (i) any recombinant DNA sequence used by LICENSEE, or expression product or any alteration or modification thereof, derived from or obtained by, or produced using PACKAGING CELLS; or (ii) a fragment of any recombinant DNA sequence or expression product derived from obtained by, or produced using PACKAGING CELLS, and (iii) provided that (i) and (ii) are based upon and/or are derived from VBL TECHNOLOGY or VBL TECHNOLOGY in combination with the genome of a serotype 5 human adenovirus.
     
  1.16 PACKAGING CELL KNOW HOW means PER.C6® KNOW HOW, MODIFIED CELLS and all materials, information, experience and data, formulae, procedures, results and specifications, regulatory filings and clinical and pre-clinical data, in written or electronic form, which are specifically related to MODIFIED CELLS, which (i) are in the possession of the Parties at the EFFECTIVE DATE or come into the possession of the Parties during the TERM of this Agreement, (ii) are not generally known (iii) are necessary for the research use of the MODIFIED CELLS, and (iv) are not subject to a third party confidentiality obligation that prevents either Party from disclosing the same.
     
  1.17 PATENT means granted patents, including utility models and certificates of invention, and reissues, reexaminations, supplementary protection certificates, extensions, and term restorations thereof, and patent applications therefore, including any continuations, continuations-in-parts, and/or divisional applications thereof, and any and all patents issuing from any of the above.
     
  1.18 PER.C6® CELL LINE or PER.C6® CELL means the cells deposited under ECACC No. 96022940, as described in Exhibit 1.18, as updated by CRUCELL from time to time in accordance with Section 3 below to include additional CELLS deposited following the EFFECTIVE DATE.
     
  1.19 PER.C6® KNOW HOW means PER.C6® CELLS and all materials, information, experience and data, formulae, procedures, processes and techniques, results and specifications, know-how, regulatory filings and clinical and pre-clinical data, which are specifically related to PER.C6® CELLS, and which are described in the PER.C6® KNOW HOW FILE, as updated by CRUCELL from time to time in accordance with Section 3 below.
     
  1.20 PER.C6® KNOW HOW FILE means the written compilation of PER.C6® KNOW HOW and PACKAGING CELL KNOW HOW, which is provided to all PER.C6® licensees, and which includes but it not limited to processing and manufacturing information and data limited to using PER.C6® CELLS and/or MODIFIED CELLS for the production of replication defective adenoviral vectors therewith.
     
  1.21 PER.C6® PATENTS mean PATENTS that CRUCELL owns, or controls by license or otherwise, wherein said license has a sublicense right, or which CRUCELL has a right to assignment, and that claim PER.C6® CELLS or the use thereof for the manufacture of replication defective adenoviral vectors, identified on Exhibit 1.21.
     
  1.22 PRODUCT means a pharmaceutical product, intended for administration to human subjects, comprising of PACKAGING CELL-EXPRESSION SEQUENCE, in final finished form.

 

 4
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  1.23 PROGRAMS means research and development programs of LICENSEE or its SUBLICENSEES in the FIELD to develop PRODUCT in the FIELD, including but not limited to any and all pre-market-registration activities and post-market-approval studies.
     
  1.24 REGISTERED AFFILIATE means an AFFILIATE or STRATEGIC PARTNER operating in APPROVED COUNTRIES to the extent identified in Exhibit \2£ which may be extended from time to time in accordance with the provisions of Section 2.1.5 below, providing full details of the name, offices and branches of such AFFILIATE or STRATEGIC PARTNER.
     
  1.25 STRATEGIC PARTNER means a reputable company with whom VBL has entered into a collaboration agreement for the co-development and / or co-marketing of pharmaceutical products, substantially discovered, researched or developed by VBL in the FIELD which either (i) enters into a material transfer agreement with CRUCELL substantially in the form of Exhibit 1.25 hereto, or (ii) does not obtain access to the PACKAGING CELLS.
     
  1.26 SUBLICENSEE means a REGISTERED AFFILIATE to which LICENSEE grants a sublicense under and in accordance with this Agreement.
     
  1.27 TERM starts on the EFFECTIVE DATE and continues as described in Section 6.1.
     
  1.28 THIRD PARTIES means any person or entity other than VBL, CRUCELL, SUBLICENSEES, AFFILIATES or STRATEGIC PARTNER.
     
  1.29 VALID PATENT CLAIM shall mean a claim in any issued and unexpired PER.C6® PATENT, which claim has not been held invalid by a non-appealed or unappealable decision by a court or other appropriate body of competent jurisdiction, provided, however, that there exists no outstanding order, injunction or other action (including any temporary relief) that impairs the rights granted under such CLAIM to LICENSEE, its SUBLICENSEES, REGISTERED AFFILIATES or Contractors, as contemplated under this Agreement. For the purpose of royalty determination and payment, any claim being prosecuted in a pending patent application in a particular country shall be deemed to be a VALID PATENT CLAIM provided such claim is not pending for more than ten (10) years from the earliest filing date to which the patent application is entitled to claim in such country (such as the first filed application based on a PCT application and claiming the PCT filing date, or the first national patent application from which subsequent patent applications claim filing date benefit) and in which case it shall cease to be considered a VALID PATENT CLAIM until a patent in the pertinent country based on such application is granted.
     
  1.30 VTS™ TECHNOLOGY means LICENSEE’S proprietary VTS™ (Vascular Targeting System) platform technology that enables control of gene expression to areas in which angiogenesis is taking place to either promote or destroy newly formed blood vessels.
     
  1.31 VBL PROPRIETARY RIGHTS shall mean, as between the Parties, all right and title in and to VBL TECHNOLOGY, PACKAGING CELL-EXPRESSION SEQUENCE and PRODUCTS, including without limitation (i) all data, results, inventions, know-how, improvements, developments or other information arising from or in connection with the PROGRAM; and (ii) any applications, improvements, modifications and derivatives of any of the above and any know-how, proprietary rights and PATENTS relating thereto or arising therefrom.
     
  1.32 VBL TECHNOLOGY shall mean, as between the Parties, replication-deficient El and E3-deleted adenovirus 5 vector or adenovirus 3 vector and conditionally replicative adenovirus (CRAD) 3 and 5 Vector, containing either the FAS-Chimera transgene or Tyrosine Kinase and VTS™ TECHNOLOGY, and any know-how related thereto and to the use thereof. At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for the transgene to be changed. Such change shall be deemed effective unless CRUCELL responds to LICENSEE’S notice within thirty (30) days of its receipt that it is withholding consent, provided such consent may only be withheld if such change would result in a technology which is either (i) directly competitive with another technology under a then existing exclusive out-license by CRUCELL, or (ii) infringes any CRUCELL’s patent which are not otherwise covered in this Agreement. For the avoidance of doubt VBL technology will contain only one (1) Transgene in combination with aforementioned either Adenovirus 3 or 5 or (CRAD) and VTS™ TECHNOLOGY.

 

 5
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

2. LICENSES; SUBLICENSING; OWNERSHIP OF CERTAIN RIGHTS; GRANT BACK LICENSE

 

  2.1 CRUCELL Grant to LICENSEE.

 

  2.1.1. CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and PER.C6® KNOW HOW, without the right to grant sublicenses except to SUBLICENSEES in accordance with the provisions of Section 2.1.4 below, (1) to use and import PER.C6® CELLS and PER.C6® KNOW HOW for the sole purpose of making MODIFIED CELLS during the course and performance of PROGRAMS; and (2) to use and import MODIFIED CELLS and PACKAGING CELL KNOW HOW during the course and performance of PROGRAMS; and (3) to use and import PACKAGING CELLS and PACKAGING CELL KNOW HOW to manufacture and to have made, in facilities of LICENSEE or its SUBLICENSEES subject to Section 2.4 below, PRODUCTS for use in the FIELD. For the avoidance of doubt, and subject to a THIRD PARTY entering first into a Material Transfer Agreement with CRUCELL prior to the transfer of any PACKAGING CELLS or PACKAGING CELL KNOW HOW as set forth in Section 2.4 below, LICENSEE is also granted hereunder the right to provide PACKAGING CELLS, PACKAGING CELL KNOW-HOW and PRODUCTS to THIRD PARTIES for bona fide contract service purposes in the course and performance of PROGRAMS and for the manufacture and making of PRODUCTS solely on LICENSEES’ behalf.
     
  2.1.2. CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and PER.C6® KNOW HOW, with the right to grant sublicenses, to develop, use, import, offer to sell, and sell PRODUCTS for use in the FIELD.
     
  2.1.3. Sublicense Requirements in General. Any agreement in which LICENSEE purports to sublicense the rights granted herein under the PER.C6® PATENTS and PER.C6® KNOW HOW, (i) shall not grant any further right to sublicense under the PER.C6® PATENTS and PER.C6® KNOW HOW nor grant any right to transfer the PER.C6® KNOW HOW or the sublicensed rights; and (ii) shall include terms at least as restrictive as those contained in this Agreement with respect to the use and exploitation of the rights granted under the PER.C6® PATENTS and PER.C6® KNOW HOW.
     
  2.1.4. Certain Sublicense Requirements - REGISTERED AFFILIATES. LICENSEE shall be permitted to sublicense its rights and obligations pursuant to Section 2.1.1 to REGISTERED AFFILIATES (without the right to further sublicense), provided each such REGISTERED AFFILIATE acknowledges and assumes all of the rights, restrictions and obligations of this Agreement applicable to such SUBLICENSEE hereunder, except, as between the Parties, for those rights and obligations for which LICENSEE shall be solely responsible as provided for herein (e.g. indicated by wording such as “on its own behalf and on behalf of its SUBLICENSEES”), in a writing signed by a duly authorized representative of such REGISTERED AFFILIATE. LICENSEE shall be responsible for assuring that each REGISTERED AFFILIATE has become fully aware of, and complies with, its rights, restrictions and obligations under this Agreement as a SUBLICENSEE prior to such REGISTERED AFFILIATE exercising any right that LICENSEE may sublicense to such REGISTERED AFFILIATE hereunder. Irrespective of any written sublicense to a REGISTERED AFFILIATE, the exercise of any sublicenseable right hereunder by a REGISTERED AFFILIATE shall be deemed to bind such REGISTERED AFFILIATE to comply with the applicable restrictions, obligations and duties hereunder, except for those obligations and duties for which LICENSEE is solely responsible as provided herein. Irrespective of the number of SUBLICENSEES, CRUCELL shall only be required to communicate with, and provide technical assistance to, LICENSEE, or one designated SUBLICENSEE, unless the Parties agree otherwise in a written and duly executed amendment hereto. LICENSEE shall be jointly and severally liable with each of its REGISTERED AFFILIATES towards CRUCELL for their compliance with the restrictions, obligations and duties hereunder.

 

 6
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  2.1.5. At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for a new AFFILIATE and/or STRATEGIC PARTNER to become a REGISTERED AFFILIATE. If Parties agree in writing that such AFFILIATE and/or STRATEGIC PARTNER shall become a REGISTERED AFFILIATE (CRUCELL’s consent not be unreasonably withheld or delayed), such AFFILIATE shall be included in Exhibit 1.2, by way of a duly executed written amendment, after CRUCELL has received the document duly executed by the respective AFFILIATE as referred to in Section 2.1.4. CRUCELL shall respond to LICENSEE’S notice within fourteen (14) days of its receipt, and shall not unreasonably withhold its consent to the addition of an Affiliate as aforesaid.
     
  2.1.6. The license grant in this Section 2 shall be effective from the date that CRUCELL receives the License Fee specified in Section 4 herein until expiration of the TERM.

 

  2.2 Restricted Access to PACKAGING CELLS.

 

The Licenses grant herein is restricted such that LICENSEE and its SUBLICENSEES shall not be permitted under the terms of this Agreement to engage in the following activities:

 

  2.2.1. to use PACKAGING CELLS (i) in or for FUNCTIONAL GENOMICS studies, (ii) for the manufacture of RECOMBINANT PROTEIN, (iii) in or for the manufacture of vaccines against communicable infectious agents, or (iv) in or for the development of products to prevent or treat diseases caused by chicken anemia virus, or to produce vectors, or expression products thereof, containing all or a part of a chicken anemia virus gene;
     
  2.2.2. to use, store, hold or otherwise deliver PACKAGING CELLS or PACKAGING CELL KNOW HOW in or to NON-APPROVED COUNTRIES;
     
  2.2.3. to offer, provide, give access to or to otherwise make available to THIRD PARTIES or to AFFILIATES that are not SUBLICENSEES, PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW, except as provided for in Section 2.3 and 2.4 below;
     
  2.2.4. to offer or provide services to THIRD PARTIES, or to AFFILIATES that are not SUBLICENSEES, relating to or using PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW.

 

 7
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  2.3 Permitted Access to PACKAGING CELLS. Sections 2.2.3 and 2.2.4 shall not apply to the extent that LICENSEE or its REGISTERED AFFILIATES or any Contractors will be required to provide, give access to or otherwise make available, by order or regulation of a governmental agency or court of competent jurisdiction, the results, materials, or know how obtained in the course of PROGRAMS, or incorporating PACKAGING CELLS or PACKAGING CELL KNOW HOW, or the sale and/or distribution of PRODUCTS. Under such circumstances, LICENSEE shall promptly notify CRUCELL of such order or regulation requiring disclosure and shall make its best efforts to cooperate with CRUCELL to preserve the confidentiality of, and CRUCELL’s proprietary interest in, the PACKAGING CELL KNOW HOW.

 

  2.4 Supply of PACKAGING CELLS to Contractors.

 

  2.4.1. Subject to the conditions stated in this Section, LICENSEE shall have the right to deliver to a fee-for-service contractor (“Contractor”), PACKAGING CELLS and PACKAGING CELL KNOW HOW (1) to conduct authorized studies of and other tasks relating to PACKAGING CELLS, solely for use by LICENSEE in PROGRAMS, and/or (2) to use PACKAGING CELLS and PACKAGING CELL KNOW HOW to develop processes and perform other tasks for the manufacture and making of, and to manufacture and make, PACKAGING CELLS and PRODUCTS. LICENSEE shall not provide PACKAGING CELLS or PACKAGING CELL KNOW HOW to a fee-for-service Contractor except pursuant to a completely executed, written PER.C6® Material Transfer Agreement (“MTA”) with CRUCELL. The Contractor shall enter into a material transfer agreement substantially in the form of Exhibit 2.4.1 hereto.
     
  2.4.2. CRUCELL shall have the right to disapprove the choice of any fee-for-service third party that is not reputable and/or reliable or operates in a NON-APPROVED COUNTRY, which disapproval shall only be asserted reasonably and upon prompt notice to LICENSEE of no later than fourteen (14) working days following receipt of such Contractor’s details with reference specifically to this section, setting forth the reasons for CRUCELL’S disapproval. For purposes of this Section7 2.4.2, “not reputable and/or reliable” shall mean, that such fee-for-service third party is located in a country or jurisdiction where CRUCELL has reason to believe in good faith (a) does not provide adequate protection for intellectual property and proprietary information or (b) does not provide adequate judicial recourse in case of misappropriation or misuse of intellectual property or proprietary information. Countries or jurisdictions that are on the U.S. Trade Representative’s annual “Special 301” Watch List shall be deemed to qualify as countries or jurisdictions that do not provide adequate protection or recourse as referred to under (i)(a) and (i)(b) above. CRUCELL has pre-approved on Exhibit 2.4.2 the third party contractors listed therein.

 

 8
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  2.5 Ownership of Certain Rights: Grant Back License.

 

  2.5.1. Except where expressly stated otherwise in this Agreement to the contrary, CRUCELL shall have no right, title and interest in and to any VBL PROPRIETARY RIGHTS (including any right to be notified thereof), provided that LICENSEE may notify CRUCELL of such information from time to time, at its sole discretion.
     
  2.5.2. LICENSEE and its REGISTERED AFFILIATES hereby agree to grant to CRUCELL a perpetual, royalty-free, non-exclusive worldwide license, with the right to sublicense, under the IMPROVEMENT PATENT RIGHTS and IMPROVEMENT KNOW HOW RIGHTS, provided that the license right under this Section shall not extend to the manufacture, use or sale of the particular PACKAGING CELL- EXPRESSION SEQUENCE(S) and/or PRODUCT(S) that are developed by LICENSEE or its SUBLICENSEES and that are the subject of this Agreement or the VBL PROPRIETARY RIGHTS.

 

 9
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

3. SUPPLY OF CELLS AND KNOW-HOW; CERTAIN UPDATES; TECHNICAL ASSISTANCE; REPORTING

 

  3.1 Supply of Cells and Know-How. Within thirty (30) days after receipt of the License Issuance Fee payment under Section 4.1.1, CRUCELL shall disclose and transfer to LICENSEE PER.C6® CELLS and the PER.C6® KNOW HOW to the extent incorporated into the most recent version of the PER.C6® KNOW HOW FILE.
     
  3.2 Updates. During the TERM, CRUCELL shall promptly provide updates (i) of the PER.C6® KNOW HOW FILE to LICENSEE as it is revised and made available by CRUCELL to all or substantially all PER.C6® licensees or to PER.C6® licensees conducting activities or granted rights similar to those contained in this Agreement, including without limitation new uses in the Field of PER.C6® CELLS and KNOW HOW, improved and updated techniques and know-how for the use of PER.C6® CELLS and PER.C6® KNOW HOW, and any known problems relating to the use of PER.C6® CELLS and PER.C6® KNOW HOW or deviations from previously provided information, all as may be applicable to the license granted to LICENSEE hereunder and (ii) of any safety or regulatory concerns that come to CRUCELL’s attention relating to the PACKAGING CELLS and PACKAGING CELL KNOW HOW.
     
  3.3 Technical Assistance. During the TERM, CRUCELL shall provide reasonable technical assistance (including guidance on know how related to the work with the PER.C6® CELLS) to LICENSEE, as may be necessary to use PACKAGING CELLS and PACKAGING CELL KNOW HOW in PROGRAMS and for the manufacture and making of PRODUCTS upon reasonable request and free of any additional cost to LICENSEE. To support the KNOW HOW transfer, LICENSEE shall be entitled, upon reasonable notice to CRUCELL, to visit CRUCELL’s facilities from time to time, but no more than five (5) days, once a year and view the production of the PER.C6® CELLS and other relevant processes and techniques relating to the making of MODIFIED CELLS, as well as to receive answers from CRUCELL’s employees regarding the use of such cells and of the PACKAGING CELL KNOW HOW, to the extent necessary for the purposes of a PROGRAM or the manufacture or making of a PRODUCT. LICENSEE shall compensate CRUCELL for technical assistance in excess of two (2) man-day visits by CRUCELL technical personnel to LICENSEE’S facilities, on an annual basis, for the first two (2) years of the TERM, on reasonable terms to be agreed in advance. A third man-day visit (or more) shall be at no additional cost if LICENSEE reports a material deviation from established PER.C6 KNOW HOW performance parameters, which deviation report requires such third man-day of technical assistance.

 

 10
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  3.4 Access and Reference to BMF: Conduct of Registration and Testing.

 

  3.4.1. LICENSEE and its SUBLICENSEES acknowledge that the BMF is owned by CRUCELL, may be filed by CRUCELL with other foreign governmental equivalents to the FDA and is confidential and of crucial importance to the Parties as well as to all other licensees of PER.C6® CELL technology. LICENSEE and its REGISTERED AFFILIATES shall have the right to review CRUCELL’s copy of the BMF filed with the FDA and other Governmental Authorities after providing CRUCELL with thirty (30) days prior notice. LICENSEE and its SUBLICENSEES shall further have the right to cross-reference the BMF as may be required for any regulatory submissions to Governmental Authorities, and upon LICENSEE’ request CRUCELL shall (i) notify the FDA (with a copy to LICENSEE) that LICENSEE and/or its SUBLICENSEES as applicable, is authorized to reference the data within the BMF; and (ii) provide LICENSEE with any and all existing BMF documentation in the possession of CRUCELL (provided that CRUCELL is legally able to do so) in so far required to support any regulatory submission LICENSEE or any of its SUBLICENSEES makes to a Governmental Authority in a country where a BMF or its foreign equivalent has not been submitted or is not in effect or may not be referenced to. CRUCELL shall notify LICENSEE of any significant update to the BMF from time to time and shall provide LICENSEE with a copy thereof upon its request as set forth above.
     
  3.4.2. LICENSEE and its REGISTERED AFFILIATES shall not be entitled to, and agree that they will not, characterize, or issue releases or certificates of analysis for, or analyze the genome of, any PACKAGING CELLS, or engage in any research of PACKAGING CELLS that concern any safety, toxicity or tumorgenicity of PACKAGING CELLS without obtaining the prior written agreement of CRUCELL, provided that, if any Governmental Authority requests additional data or characterization of PACKAGING CELLS that CRUCELL chooses not to provide LICENSEE shall have the right to perform its own studies solely as required by the Governmental Authority, and to provide the results to the requesting Governmental Authority. Failure by CRUCELL to provide LICENSEE with such information or data for delivery to the applicable Governmental Authority within a reasonable period that shall enable LICENSEE to adequately respond to any Governmental Authority request shall be deemed as CRUCELL choosing not to provide same. The aforementioned restrictions shall only apply with respect to PACKAGING CELLS, and not PACKAGING CELL-EXPRESSION SEQUENCE or PRODUCT, the analysis of which shall be at the sole discretion of LICENSEE and not subject to any approval of CRUCELL.
     
  3.4.3. LICENSEE further agrees to use its reasonable efforts to promptly notify Crucell of any and all communications to and from Governmental Authorities directly relating to the safety of PACKAGING CELLS and agrees to consult promptly with Crucell to resolve any such concerns with the FDA or such other Governmental Authorities, Noncompliance by LICENSEE with the obligation to use its reasonable efforts to obtain prior agreement of CRUCELL prior to any characterization, release or certificate issuances of PACKAGING CELLS as set forth in Section 3.4.2 above, or to promptly notify and consult with CRUCELL in its efforts to resolve any such issues with the FDA or other Governmental Authorities as set forth in this Section 3.4.3 shall be considered to constitute a failure to comply with a material condition or covenant of this Agreement to which Section 6.5 herein applies.

 

  3.5 Reporting.

 

  3.5.1. LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on a bi-yearly (six(6)-month) basis about (1) any communication with Governmental Authorities about PACKAGING CELLS, and (2) results of any testing performed on the PACKAGING CELLS. A template for use in complying with the bi-yearly reporting obligation is attached as Exhibit 3.5.1.

 

 11
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  3.5.2. LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on an annual basis, on or before the anniversary of the EFFECTIVE DATE, with a detailed report of the data relating specifically to PACKAGING CELL performance, PACKAGING CELL KNOW HOW, as well as the operating, culturing and manufacturing parameters and data resulting from its use of the PACKAGING CELLS during the course of the PROGRAM. To facilitate the mutually beneficial resolution of any PACKAGING CELL technical performance issue, if any, LICENSEE hereby agrees to discuss with CRUCELL technical personnel relevant technical data to assist in resolving such issues. A template for use in complying with the annual reporting obligation is attached as Exhibit 3.5.2.
     
  3.5.3. It is agreed and understood that LICENSEE shall not be obligated to disclose any information, data or know-how relating to VBL PROPRIETARY RIGHTS unless and to the extent it is directly related to PACKAGING CELLS and/or their use hereunder. In such event, any and all disclosed information, data or know-how shall not be used or disclosed without LICENSEE’S prior written consent, which consent may be withheld at its sole discretion.
     
  3.5.4. LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall promptly notify CRUCELL in writing of any substantial deviations from established PER.C6® CELL characteristics and/or performance parameters included in PER.C6® KNOW HOW, prior to any notification by LICENSEE or its SUBLICENSEES to any other entity other than to the appropriate Governmental Authorities such as the FDA.
     
  3.5.5. Subject to the provisions of Section 3.5.3, information reported to CRUCELL pursuant to Sections 3.5.1 through 3.5.4 may be used by CRUCELL to assist LICENSEE in the successful implementation of PACKAGING CELL KNOW HOW, resolving technical and regulatory issues respecting PACKAGING CELL and the BMF, to amend and/or annotate the collection of PER.C6® KNOW HOW for delivery to PER.C6® licensees and/or to update the BMF, which PER.C6® KNOW HOW and BMF shall only be disclosed under conditions of confidentiality. Except as expressly stated in Sections 2.5.2, 2.5.3 and 2.5.4 above, CRUCELL shall not use any information or know-how relating to PRODUCT(S) or PACKAGING CELL EXPRESSION SEQUENCE(S) that are developed by LICENSEE or its SUBLICENSEES, or relating to any VBL PROPRIETARY RIGHTS, nor disclose any of the above to any licensee or other third party (including any Governmental Authority) without the prior written consent of LICENSEE, which consent may be withheld at its sole discretion.

 

4. LICENSE FEES

 

  4.1 License Fees. In consideration of the licenses granted and the PER.C6® KNOW HOW supplied hereunder, LICENSEE shall pay the following amounts to CRUCELL during the TERM:

 

  4.1.1. Within ten (10) days from the EFFECTIVE DATE, a License Issuance Fee of € 75,000 (seventy-five thousand Euros), exclusive of V.A.T.; and
     
  4.1.2. Starting on the first anniversary date of the EFFECTIVE DATE, an Annual License Maintenance Fee of € 100,000 (one hundred thousand Euros), exclusive of V.A.T., to be paid in arrears.

 

 12
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  4.2 Development Milestone Payments: LICENSEE shall pay CRUCELL non-creditable and non-refundable payments of € 400,000 (four hundred thousand Euros), exclusive of V.A.T., with respect to each PRODUCT for which a Governmental Authority grants marketing approval, within thirty (30) days of the issuance of the first regulatory marketing approval letter from such Governmental Authority for the first indication for each such PRODUCT. Payment under this Section 4.2 shall be made once for each unique PRODUCT.
     
  4.3 Running Royalty. LICENSEE shall pay to CRUCELL a running royalty (the “Running Royalty”) as follows:

 

  4.3.1. If PACKAGING CELLS and/or PACKAGING CELL KNOW-HOW are, or were, used in the development, use, manufacture, importation or sale of the PRODUCT, a Running Royalty of one and half a percent (1.5%) of the NET SALES for the duration of ten (10) years from the FIRST COMMERCIAL SALE of the PRODUCT;
     
  4.3.2. If the use, manufacture, importation or sale of the PRODUCT comes under the scope of at least one VALID PATENT CLAIM, on a country by country basis, a Running Royalty of half a percent (0.5%) of NET SALES.
     
  4.3.3. Only one Running Royalty, that may be either a Know-How Royalty (Section 4.3.1), or a Patent Royalty (Section 4.3.2) or a combination of the Know-How and Patent Royalties (1.5 + 0.5 = 2.0%), shall be due for each unique PRODUCT.

 

5. PAYMENTS; BOOKS AND RECORDS

 

  5.1 Royalty Reports and Payments. After the FIRST COMMERCIAL SALE of the PRODUCT on which Running Royalties are required, LICENSEE shall submit quarterly written reports to CRUCELL within ninety (90) days after the end of each calendar quarter, stating in each such report the number, description, and aggregate NET SALES of the PRODUCT sold during the calendar quarter upon which a Running Royalty is payable under Section 4 above. Concurrently with the submission of such reports, LICENSEE shall pay to CRUCELL Running Royalties at the rate specified in Section 4.
     
  5.2 LICENSEE Obligations. LICENSEE shall be solely responsible for the payment to CRUCELL of any royalties, license fees and milestone or other payments due from its AFFILIATES and/or SUBLICENSEES, and for any payments to THIRD PARTIES under licenses or similar agreements between LICENSEE and such THIRD PARTIES necessary to allow the manufacture, use or sale of the PRODUCT by LICENSEE, or SUBLICENSEES;

 

  5.3 Method of Payment.

 

  5.3.1. All payments due hereunder to CRUCELL shall be paid in Euros in immediately available funds, for CRUCELL’s account, to a bank designated in writing by CRUCELL. CRUCELL shall provide LICENSEE with an invoice prior to the due dates specified in Section 4.1.2 and 4.2, and LICENSEE shall pay such invoices within the later of the applicable due date or thirty (30) days of receipt by LICENSEE. If the invoice is received later than the due date, then LICENSEE shall have thirty (30) days from the receipt of the invoice to pay the invoiced amount.

 

 13
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  5.3.2. CRUCELL shall submit an invoice to LICENSEE for all transportation, packing or other documented and reasonable costs incurred on LICENSEE’S benefit and at LICENSEE’S request pursuant to this Agreement in connection with providing PACKAGING CELL KNOW HOW to LICENSEE, and approved in advance by LICENSEE. LICENSEE shall pay invoices specifying these reasonable costs within thirty (30) days of receipt.
     
  5.3.3. Inflation Index Adjustment: Commencing from the first (1st) anniversary date of the EFFECTIVE DATE, license fees due under Section 4.1 shall be increased by two and one half percent (2.5%) upon each anniversary of the EFFECTIVE DATE until and including the eighth anniversary of the EFFECTIVE DATE.

 

  5.4 Interest. IF LICENSEE fails to make any payment under this Agreement within ninety (90) days of the date on which the same becomes due and payable, LICENSEE shall owe CRUCELL interest at the rate of twelve and a half percent (12.5%) per annum (as determined on the date the payment first becomes due) on any outstanding amount until payment is made in full. If parties are in dispute on the amount of royalties payable pursuant to Clause 5.1, the penalty becomes due only after Parties have agreed on the exact royalty amount due.
     
  5.5 No Refunds. Payments referred to in this Section 5 shall not be refundable under any circumstances, including but not limited to the termination of this Agreement for whatever reason.
     
  5.6 Currency Conversion. If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the following procedures: Sales recorded during a month will be translated to Euro values at the rate of the 1st working day of that month based on the exchange rates published on the OANDA website. Any changes to procedures for currency conversion shall only apply after such notice has been delivered and provided that such changes are consistently applied across LICENSEE’S operating units and continue to maintain a set methodology for currency conversion.
     
  5.7 Withholding Taxes. If LICENSEE is required by any applicable law, rule or regulation to make any deduction or withholding for or on account of any Tax (as defined below) from any payment to be made to CRUCELL under this Agreement, then LICENSEE shall (i) promptly notify CRUCELL of such requirement, (ii) pay to the relevant authorities the full amount required to be deducted or withheld promptly upon determining that such deduction or withholding is required or receiving notice that such amount has been assessed against CRUCELL, and (iii) promptly forward to CRUCELL an official receipt, or certified copy or other documentation reasonably acceptable to CRUCELL, evidencing such payment to such authorities.

 

  5.7.1. If CRUCELL is entitled to an exemption from or reduction of withholding tax under any applicable law or treaty with respect to any payments made hereunder, CRUCELL shall deliver to LICENSEE at the time or times prescribed by applicable law or reasonably requested by LICENSEE, such properly completed and executed documentation prescribed by applicable law as will permit such payments to be made without withholding or at a reduced rate.
     
  5.7.2. For purposes of this Section, the term “Tax” shall mean any present or future tax, levy, impost, duty, charge, assessment or fee of any nature (including interest, penalties and additions thereto) that is imposed by any government or other taxing authority in respect of a payment under this Commercialization Agreement.

 

 14
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  5.8 Records: Inspection. LICENSEE shall and shall cause its REGISTERED AFFILIATES and its SUBLICENSEES to keep complete, true and accurate books of account and records for the purpose of determining the Running Royalty amounts payable under this Agreement. Such books and records shall be required to be kept at the principal place of business of LICENSEE, REGISTERED AFFILIATES and SUBLICENSEES, as the case may be, for at least three (3) years following the end of the calendar quarter to which they pertain. The records of LICENSEE and its REGISTERED AFFILIATES, including all payments received from their SUB LICENSEES, will be open for inspection during such three (3) year period by an independent public accounting firm of national prominence retained by CRUCELL and acceptable to LICENSEE for the purpose of verifying the Running Royalty statements. Such inspections may be made no more than once each calendar year, at reasonable times mutually agreed to by LICENSEE and CRUCELL. CRUCELL’s representative or agent will be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section shall be at CRUCELL’s expense, unless a variation or error producing an increase exceeding ten percent (10%) of the Running Royalty amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable and customary costs relating to the inspection for such period will be paid by LICENSEE.

 

6. TERM AND TERMINATION

 

  6.1 Agreement Term. This Agreement shall become effective as of the EFFECTIVE DATE and, unless earlier terminated pursuant to the other provisions of this Section, shall continue in full force and effect on a country-by-country and product-by-product basis, until LICENSEE has no remaining obligation to pay to CRUCELL the Running Royalty in accordance with Section 4.3. Thereafter, LICENSEE shall have a fully paid up, world wide, royalty free, perpetual license right under the PER.C6® PATENTS and PER.C6® KNOW HOW to continue to make, have made, import, use, offer for sale and sell the PRODUCT(S) in such countries.
     
  6.2 Termination by LICENSEE. LICENSEE may terminate this Agreement by giving CRUCELL three (3) months prior written notice, and payment of all outstanding monies owed to CRUCELL until the date of termination, such as pro rata payment of arrears obligations pursuant to Section 4.1.2, which payment is due prior to actual termination of the Agreement.
     
  6.3 Termination by Mutual Agreement. This Agreement may be terminated upon mutual written agreement between the Parties.
     
  6.4 Termination Upon Insolvency or Bankruptcy. Either Party may terminate this Agreement, by notice to the other Party with immediate effect, if (a) the other Party (i) pledges substantially all of its assets for the benefit of creditors, and the conditions for the creditors to enforce their rights to control those assets have been satisfied (such as the expiration of a cure period for an uncured default), (ii) pledge any portion of PER.C6® KNOW HOW for the benefit of creditors, or (iii) institutes, consents to or fails to diligently oppose any proceeding seeking to adjudicate it a bankrupt or insolvent or (b) any proceeding is instituted against or in respect of the other Party by third parties seeking bankruptcy relief and such proceeding continues undismissed, or unstayed and in effect for a period of 60 days after the institution thereof.
     
  6.5 Termination by Default. If either Party defaults in the performance of, or fails to be in compliance with, any material condition or covenant of this Agreement and any such default or noncompliance shall not have been remedied, or steps initiated to remedy the same, to the other Party’s reasonable satisfaction, within three (3) months for payment defaults, and within six (6) months for other defaults or non-compliance, after receipt by the defaulting Party of a written notice thereof from the other Party, the Party not in default may, without further notice, forthwith terminate this Agreement at its option, provided, however, that in the event of breach by CRUCELL, accrual and payment of any amounts due to it hereunder shall be suspended during the cure period; and provided, further, that in the event of a dispute as to default, non-compliance or right to terminate this Agreement, this Agreement shall continue until such dispute is finally resolved pursuant to Section 10.3 hereof.

 

 15
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  6.6 Rights and Obligations on Term, Termination, or Suspension.

 

  6.6.1. Unless expressly provided to the contrary, the following provisions shall survive the termination of this Agreement: Sections 1, 2.3, 2.5, 3.5.4, 3.5.5, 6.6, 6.7, 7, 8, 9 and 10 hereof.
     
  6.6.2. Return of PACKAGING CELL KNOW HOW. Except in the case of termination by LICENSEE for default pursuant to Section 6.5, upon early termination of this Agreement by either Party, at CRUCELL’S written request, LICENSEE and its SUBLICENSEES shall destroy all supplies of PACKAGING CELL KNOW HOW, and shall promptly thereafter confirm such destruction in writing to CRUCELL, except for one copy of such written information to be retained in confidential files and to be used solely to establish rights and obligations under this Agreement, and for no other use or purpose.

 

  6.7 Termination by either Party pursuant to this Article shall not prejudice any other remedy that a Party might have at law or equity.

 

7. CONFIDENTIALITY

 

  7.1 Confidentiality Obligations. Each Party shall maintain in confidence all information disclosed or otherwise made available by the other which is identified as confidential and which is confirmed in writing and marked “confidential” or otherwise properly labeled as confidential within thirty (30) days of such original disclosure, including without limitations, information relating to PACKAGING CELL KNOW HOW and PROGRAMS or results of PROGRAMS (all such information hereafter referred to as “INFORMATION”), and shall not use such INFORMATION or disclose the same to anyone, except (i) that LICENSEE may disclose CRUCELL’S INFORMATION to its REGISTERED AFFILIATES, SUBLICENSEES and Contractors, those of its agents, direct employees, consultants and investigators to the extent necessary for the execution of PROGRAMS and manufacturing and sale of PRODUCTS, as set out in this Agreement; (ii) that LICENSEE may disclose CRUCELL’S INFORMATION, as well as its engagement with CRUCELL’s hereunder and the use of PER.C6® CELLS, PATENTS and KNOW HOW, as required to Governmental Authorities; (iii) that CRUCELL may disclose LICENSEE’S INFORMATION to its agents, direct employees, consultants and investigators who have a need-to-know for the performance of this Agreement; the foregoing as permitted by this Agreement and subject to the responsibilities and obligations as set forth in this Agreement. Either Party may disclose the other Party’s PROGRAMS or results of PROGRAMS to potential investors and other financing sources, investment bankers, advisors, attorneys, accountants and/or STRATEGIC PARTNERS within the course of a good faith due diligence inquiry to the extent relevant for the purpose of the inquiry. The foregoing is subject to the below:

 

 16
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  7.1.1. Prior to such permitted disclosure to such LICENSEE, REGISTERED AFFILIATES, SUBLICENSEES, Contractors, agents, direct employees, consultants, investigators, potential investors and other financing sources, investment bankers, advisors, attorneys, accountants and strategic investors, disclosure must be subject to the provisions of a confidentiality agreement containing restrictions no less stringent than the obligations set forth in this Section 7.1 as such restrictions apply to LICENSEE, provided that attorneys and accountants shall not be required to execute such agreement if so informed of the confidential obligations hereunder and provided their professional code of conduct requires that such confidentiality obligations be so observed.
     
  7.1.2. Each Party shall use a similar effort to that which it uses to protect its own trade secrets or proprietary information (but that in any event be no less than customary industry standards) to protect the other Party’s INFORMATION and to ensure that its applicable AFFILIATES, SUBLICENSEES and Contractors (if any), agents, direct employees, consultants, investigators, potential investors and strategic investors do not disclose or make any unauthorized use of such INFORMATION. Each Party shall notify the other promptly of its knowledge of any unauthorized use or disclosure of the other’s INFORMATION and reasonably assist it to enforce rights against such use or disclosure.

 

  7.2 Exceptions. The confidentiality and non-use obligations under this Agreement shall not apply to the extent that:

 

  7.2.1. the Party who has received the INFORMATION (“RECIPIENT”) is required to disclose information by order or regulation of a governmental agency or court of competent jurisdiction subject to the provisions of Section 7.3.3 below; or
     
  7.2.2. the RECIPIENT can demonstrate that

 

  7.2.2.1. the disclosed INFORMATION was at the time of such disclosure by RECIPIENT already in the public domain, or falls into the public domain thereafter, other than as a result of actions of RECIPIENT, its agents, direct employees, consultants or investigators, or in violation hereof;
     
  7.2.2.2. the disclosed INFORMATION is independently developed without use or regard to the INFORMATION (as shown by RECIPIENT’S written records); or
     
  7.2.2.3. the disclosed INFORMATION was lawfully known by RECIPIENT (as shown by its written records) prior to the date of disclosure to RECIPIENT without an obligation of secrecy, from sources legally entitled to disclose the same without an obligation of secrecy or received by RECIPIENT (as shown by its written records) on an unrestricted basis from a source unrelated to any Party to this Agreement and not, to its knowledge, under a duty of confidentiality.
     

 

  7.3 Publications and Public Announcements:

 

  7.3.1. Each party shall have the right to publish the existence of this Agreement, but not the terms thereof, with the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed.

 

 17
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  7.3.2. Any disclosure which is required by law may be made without the prior consent of the other Party, although the other Party shall be given prompt notice of any such legally required disclosure and an opportunity to comment on, and attempt to challenge or limit the proposed disclosure reasonably in advance to the extent feasible.
     
  7.3.3. Furthermore, the disclosing Party shall make diligent efforts to limit the nature and scope of any disclosure to the extent reasonably possible and to otherwise prevent the disclosure of the non-disclosing Party’s INFORMATION.

 

8. PATENTS

 

 

 

8.1 CRUCELL shall be responsible and use commercially reasonable efforts for the prosecution, protection and maintenance of the PER.C6® PATENTS throughout the TERM, and shall bear all costs, fees and expenses in connection thereto.
     
  8.2 If either Party after the EFFECTIVE DATE is warned or sued by a third party alleging or charging infringement of any patents or published patent applications or any other rights, due to or in connection with the use of PACKAGING CELLS, or the practice of any of the PER.C6® PATENTS or PACKAGING CELL KNOW-HOW, by either Party, the Party which is warned or sued, shall notify promptly the other Party.
     
  8.3 CRUCELL shall be responsible, at its expense, for settling and/or defending any warning or litigation, for patent infringement in which the alleged infringing process or product giving rise to liability for damages involves or arises from use by CRUCELL of PACKAGING CELLS or the practice of any of the PACKAGING CELLS, PER.C6® PATENTS or PACKAGING CELL KNOW-HOW.
     
    In so far as any such infringement action, or the settlement or defense thereof, might have an effect on LICENSEE activities, the applicable Party shall promptly inform the other Party of such claim and (i) CRUCELL and LICENSEE shall confer as to any modification of any right granted to LICENSEE hereunder, provided, that such modification shall not substantially alter LICENSEE’S rights hereunder; (ii) LICENSEE shall be entitled, but shall not be obligated, to attempt to obtain a license from such third party for the right to use such third party’s patent or other applicable right and (iii) in the event that LICENSEE is named thereunder, it shall have the right to participate in the defense of such claim. In any event, if such infringement action might have an effect on LICENSEE activities (i) upon CRUCELL’s written request, LICENSEE agrees to reasonably assist CRUCELL in any such defense; and (ii) LICENSEE shall be entitled to immediately terminate this Agreement.
     
    If LICENSEE should suffer any out of pocket costs and other expenses, including reasonable attorney’s fees, as a result of the assistance in such dispute, CRUCELL shall reimburse LICENSEE such out of pocket costs and expenses incurred by LICENSEE.
     
    LICENSEE shall be responsible, at its expense, for settling and/or defending any warning or litigation for patent infringement made against CRUCELL, in which the alleged infringing process or product giving rise to liability for damages involves use by LICENSEE of PACKAGING CELLS. If CRUCELL should suffer any damages, out of pocket costs and other expenses and liabilities as a result of such dispute, including reasonable attorney’s fees (collectively “Losses”), LICENSEE shall indemnify CRUCELL and its AFFILIATES and hold them harmless against any such Losses.

 

 18
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  8.4 No Party shall enter into any settlement which admits or concedes that any aspect of the PATENT or know how of the other Party is invalid or unenforceable in any way, without the prior written consent of such other Party.

 

9. REPRESENTATIONS; WARRANTY, INDEMNIFICATION

 

  9.1 CRUCELL Representations and Warranties. CRUCELL represents and warrants that (a) CRUCELL has the full legal right to enter in this Agreement and to perform its obligations thereunder; (b) CRUCELL will not be violating any law, regulation, order or contractual or other obligations of or applicable to CRUCELL or to the PER.C6® CELLS, PER.C6® PATENTS or PER.C6® KNOW-HOW by executing, delivering or performing this Agreement, and neither the execution or delivery of this Agreement shall not conflict with or violate any such law, regulation, order or contractual or other obligation; (c) CRUCELL has duly executed and delivered this Agreement, which constitutes a legal, valid and binding obligation of CRUCELL, enforceable against CRUCELL in accordance with its terms; (d) CRUCELL is the legal owner of all rights and title in and to the PER.C6® CELLS, PER.C6® PATENTS and PER.C6® KNOW HOW licensed hereunder, free and clear of any encumbrance, charge or restriction, and has the right to grant LICENSEE the licenses granted under this Agreement without conflicting with any third party rights and without creating any encumbrance, charge or restriction in connection therewith; (e) the PER.C6® CELLS provided to LICENSEE or to a designated contractor under 2.1.4 (i) comply with the certificates of analysis that accompany the cells, (ii) comply with the specifications as set forth in the Exhibits hereto, and (iii) have been manufactured, tested and maintained according to the current ICH, FDA and EMEA guidelines; (f) the terms of this Agreement do not create a conflict with or result in the breach of any right, obligation or agreement that CRUCELL has with any third party; (g) it has been using and out-licensing the PER.C6® CELLS since 1998 and it has never received any written, oral or electronic communication alleging that the PER.C6® CELLS, PER.C6® PATENTS or PER.C6® KNOW-HOW or the use thereof infringes the intellectual property rights of any third party nor is it currently aware of any circumstances that may give rise to any such claim; and (h) CRUCELL has and will continue to prosecute, maintain and take other actions necessary, to support the continued validity and enforceability of the PER.C6® PATENTS during the TERM and there is no pending claim or litigation, or, to CRUCELL’s knowledge, threatened claim, contesting the validity, ownership or right to use or license the PER.C6® PATENTS. UNLESS OTHERWISE EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, CRUCELL DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, FITNESS FOR ANY PARTICULAR PURPOSE, RESPECTING ANY MATERIALS PROVIDED TO LICENSEE PURSUANT TO, OR IN ASSOCIATION WITH THE PERFORMANCE OF THIS AGREEMENT, INCLUDING ANY WARRANTIES CONCERNING THE INHERENT PROPERTIES OF PACKAGING CELLS SUPPLIED UNDER THIS AGREEMENT. EXCEPT AS SET FORTH IN THIS AGREEMENT, CRUCELL MAKES NO WARRANTY AS TO THE MERCHANTABILITY OF THE PRODUCTS, PER.C6® KNOW HOW OR PER.C6® PATENTS.
     
  9.2 LICENSEE Warranties. LICENSEE (a) is entitled to enter in this Agreement and to perform its obligations thereunder; (b) LICENSEE does not violate any law, regulation, order or its existing contractual obligations by executing, delivering and performing this Agreement; and (c) LICENSEE has duly executed this Agreement, which constitutes a legal valid and binding obligation of LICENSEE, enforceable against LICENSEE in accordance with its terms.
     
  9.3 Product Liability and Indemnification. CRUCELL shall not be liable for and LICENSEE shall indemnify CRUCELL and hold CRUCELL harmless against any and all Losses (including product liability), arising in any manner from the use by LICENSEE or its AFFILIATES of PACKAGING CELLS and/or the PACKAGING CELL KNOW HOW, or the development or manufacture of prototypes or clinical supplies by LICENSEE or its AFFILIATES practicing PACKAGING CELLS and/or the PACKAGING CELL KNOW HOW, or the use of any PRODUCT by any human being, regardless of whether such use was contemplated by the Parties, except to the extent such liabilities result from (i) the willful misconduct, gross negligence or written instructions of CRUCELL; and/or pursuant to Section 8.3 above; and/or (ii) any breach of this Agreement by CRUCELL. CRUCELL shall hold harmless LICENSEE and its AFFILIATES against all Losses arising from the events set forth in clauses (i) and (ii) immediately above.

 

 19
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

10. MISCELLANEOUS/ RULES OF CONSTRUCTION

 

  10.1 Amendment. This Agreement may not be changed, modified, amended, or supplemented except by a written instrument signed by authorized representatives of both Parties hereto.
     
  10.2 Assignability. LICENSEE’S rights and obligations in this Agreement may not be assigned without the prior written consent of CRUCELL, except to an AFFILIATE, or in the event of a merger or sale of all, or substantially all, of LICENSEE’S assets relating to the subject matter of this Agreement to an assignee, provided that LICENSEE shall remain joint and severally liable with any such assignee for the performance of its assigned obligations hereunder if LICENSEE continues to conduct business following such sale. Such assignment shall then be binding upon, inure to the benefit of the Parties, and be enforceable. Any attempted assignment contrary to the terms of this provision shall be void.
     
  10.3 Choice of Law and Dispute Resolution. This Agreement shall be governed by and construed under the laws of the Netherlands. If any dispute arises out of this Agreement, the Parties will themselves endeavor to settle such dispute amicably. If the Parties fail to through reference to the Parties’ respective Chief Executive Officers. If the Chief Executive Officers are unable to resolve the dispute within thirty (30) days after such dispute is referred to them, then the Parties shall be subject arbitration before a single arbitrator, such arbitration to be held in accordance with the rules of arbitration of the International Chamber of Commerce and to be held in the English Language in The Hague, Netherlands The Parties shall use good faith efforts to expedite the arbitration. The Parties agree that any judgment of the foregoing arbitrator shall be final and binding and shall be enforceable in any competent court having jurisdiction over the adjudged party. Nothing herein shall prevent either party from seeking injunctive relief or other equitable remedies in or out of law.
     
  10.4 Expenses. Each Party shall bear its own expenses, if not expressly agreed otherwise in this Agreement.
     
  10.5 Force Majeure. Neither LICENSEE nor CRUCELL shall be liable for any failure or delay in performance under this Agreement which is due in whole or in part directly or indirectly to any cause of any nature beyond the reasonable control of such Party.
     
  10.6 Further Assurances. Each Party hereto agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

 20
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  10.7 Notice and Reports. All notices required by this Agreement shall be in writing, Al! notices and reports shall be sent by fax followed by registered airmail to the Parties at the following addresses or such other addresses as may be designated in writing by the respective Parties:

 

To CRUCELL: CRUCELL HOLLAND B.V.
Archimedesweg 4  
P.O. Box 2048  
2301 CA Leiden  
THE NETHERLANDS  
Attn: Business Development  
FAX: +31-71-5199800  
   
To LICENSEE: VASCULAR BIOGENICS Ltd.
6 Jonathan Netanyahu Street,  
60376, Or-Yehuda,  
ISRAEL  
Attn: Emmanuel Elalouf  
VP Business Development  
FAX: 972-3-6346449  

 

Any notices shall be deemed given when received by the other Party.

 

  10.8 Relationships of the Parties. Both Parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute CRUCELL and LICENSEE as agents, partners or joint ventures with respect to this Agreement. Neither Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract, agreement, or undertaking with any third party.

 

  10.9 Rules Of Construction.

 

  10.9.1. Captions. Paragraph captions are inserted for convenience only and in no way are to be construed to define, limit or affect the construction or interpretation hereof.
     
  10.9.2. Entire Agreement. This Agreement contains the entire agreement of the Parties regarding the subject matter hereof, and supersedes all prior agreements, understandings, and negotiations between the Parties regarding the same.
     
  10.9.3. “Including”. The words “include”, “including” or “included” are used to indicate that the matters listed are not a complete enumeration of all matters covered and should be read such as “including but not limited to”.
     
  10.9.4. Singular, Plural, Gender. Words denoting the singular, shall include the plural and vice versa. Words denoting one gender shall include all others.
     
  10.9.5. Severability. If any part of this Agreement shall be held invalid and/or unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect provided that such provisions will permit the transaction contemplated herein to take place in substantially the same manner as originally contemplated by the Parties.

 

 21
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Commercial License Agreement PER.C6®

Crucell Holland - Vascular Biogenics

 

  10.9.6. Translations. This Agreement has been written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement. In the event of any conflict in interpretation between the English version and such translation of this Agreement, the English version shall prevail.
     
  10.9.7. Waiver. The waiver by either Party of a breach of any provisions contained herein shall be in writing and shall in no way be construed as a waiver of any prior or succeeding breach of such provision or the waiver of the provision itself.
     
  10.9.8. Trademarks. PER.C6® is a registered trademark of CRUCELL. All right title and interest therein shall remain with CRUCELL. CRUCELL is solely entitled to all goodwill accruing in the trademark PER.C6® as a consequence of the use thereof by LICENSEE or otherwise. LICENSEE may only use CRUCELL’s PER.C6® trademark upon the execution of a separate trademark license agreement with CRUCELL. Notwithstanding the aforementioned, for the avoidance of doubt LICENSEE can use the PER.C6® trademark for reference purposes in connection with research publications as well as regulatory filings.
     
  10.9.9. Use of Party’s Name. No right, express or implied, is granted by this Agreement to LICENSEE to use in any manner other than for regulatory submission purposes the name “CRUCELL” or “INTROGENE”, or to CRUCELL to use in any manner the name of LICENSEE or its Affiliates, or any other trade name, logo or trademark of the other party in connection with the performance of this Agreement without prior permission from such other party except as elsewhere permitted under this Agreement.

 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement to be effective as of the date the last Party signs below.

 

VASCULAR BIOGENICS LTD.   CRUCELL HOLLAND B.V.
         
By:   By:
        Crucell N.V., represented by
         
  Or-Yehuda, ______________ 2011     Leiden ____________________, 2011

 

 22
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 1.18 - CELL LINE DESIGNATION: PER.C6®

 

Origin of the Cell Line

 

PER.C6® cells are [***] transformed with [***] of [***]. The estimated copy number is [***]. The [***] in the construct is driven by the [***]. The [***] are derived from [***].

 

Cell Line Passage History

 

Research Master Cell Bank [***] was stored at passage number [***] on 17 January 1996. Research Working Cell Bank [***] was generated from [***] and stored at passage number [***] on 7 February 1996. The cell banks are stored in the [***] of [***] at [***] in [***].

 

Components Used For Culture of the Cells

 

[***] with [***] and, optionally, [***],[***] was used for [***].

 

Quality Control

 

All work on the development of PER.C6® cells carried out at Crucell Holland has been carried out under controlled conditions. The data have been reviewed by QA Crucell Holland. The research Master Cell Bank and research Working Cell Bank have been tested by GLP-inspected contract testing companies. All recorded data mentioned have been reviewed by Quality Assurance, Crucell Holland BV, Leiden. All final reports have been reviewed for compliance to the specifications and pertinent relevant regulatory requirements from the US and EEC.

 

 23
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Safety Tests on the PER.C6® Human Adenoviral Packaging cell Line

 

Research Master Cell Bank

 

Test Result
[***] [***]

 

Research Working Cell Bank

 

Test Result
[***] [***]

 

 24
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 1.2 - APPROVED COUNTRIES

 

United States of America

 

Canada

 

The member states of the European Union on the EFFECTIVE DATE

 

Israel

 

Japan

 

Australia

 

New Zealand

 

 25
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 1.21 - PER.C6® PATENTS

 

National patents corresponding to [***] ([***];[***],[***]). The currently filed members of patent family [***] claim priorities based on European priority documents [***] ([***]) and [***] ([***]). Members of this patent (application) family further include:

 

Applications   Filing Date   Published   Publication
[***]   [***]   [***]   [***]

 

Patents   Issue Date
[***]   [***]

 

2. Claims covering the PACKAGING CELLS and the use thereof, excluding claims specifically directed to [***],[***] complementing cells and vectors, in all PATENTS entitled to claim rights from [***] ([***];[***]:[***]) of the patent family [***] of [***] that claim priority from French priority document [***] ([***]). PATENTS that include the aforesaid claims and that are granted as of the EFFECTIVE DATE are listed below:

 

[***]  

 

3. PATENTS entitled to claim rights from [***] to [***], which application claims priority from [***]. PATENTS that are granted as of the EFFECTIVE DATE include [***].

 

 26
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 1.24 - REGISTERED AFFILIATES

 

 27
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 1.25 - FORM OF MATERIAL TRANSFER AGREEMENT FOR STRATEGIC PARTNER

 

 28
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

MATERIAL TRANSFER AND CONFIDENTIALITY AGREEMENT
FOR STRATEGIC PARTNER

 

This Material Transfer and Confidentiality Agreement (“Agreement”) is by and between

 

Crucell Holland B.V., a Dutch company with offices located at Archimedesweg 4, 2333 CN Leiden, the Netherlands, hereinafter referred to as “Crucell”; and

 

Vascular Biogenics Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter referred to as “Vascular Biogenics”), and

 

[X], a company with offices located at ..............., hereinafter referred to as “Strategic Partner”.

 

(Hereinafter individually referred to as “Party” and collectively as “Parties”)

 

WHEREAS Crucell is the owner of a proprietary PER.C6® cell line (hereinafter referred to as “PER.C6® CELLS”), and of related proprietary and confidential information and patent rights (“PER.C6® CELL KNOW-HOW”);

 

WHEREAS Crucell and Vascular Biogenics have signed a commercial license agreement that employs PER.C6® CELLS and PER.C6® CELLS modified by incorporating technology of VBL (collectively with PER.C6® CELLS, “PACKAGING CELLS”) to manufacture, use and develop a pharmaceutical products in certain fields, effective as of April 15, 2011, which is attached as Exhibit A hereto (the “License”);

 

WHEREAS Vascular Biogenics and Strategic Partner have agreed to enter into a strategic alliance (the “Alliance”) with Strategic Partner involving PACKAGING CELLS and related proprietary and confidential information (“INFORMATION”), including, without limitation, related know-how (“PACKAGING CELL KNOW HOW”) on the condition that Strategic Partner enter into this Agreement with Vascular Biogenics and Crucell;

 

WHEREAS Crucell is willing to make available the PER.C6® CELL KNOW-HOW to Strategic Partner for the performance of the Alliance;

 

WHEREAS the Parties wish to make arrangements with respect to the use by Strategic Partner of the PACKAGING CELLS

 

NOW THEREFORE, the Parties hereto, intending to be legally bound, agree as follows:

 

1. Supply of Know How: Crucell agrees to provide and consents to Vascular Biogenics providing the PACKAGING CELLS and the INFORMATION to Strategic Partner upon the execution of this Agreement; solely for use under the Alliance within the scope of the PROGRAM (as defined in the License). If Crucell is requested to deliver PER.C6® CELLS and PER.C6® CELLS KNOW-HOW to Strategic Partner, Crucell shall ship the PER.C6® CELLS and PER.C6® CELL KNOW-HOW to Strategic Partner at Vascular Biogenics’ expense.
   
2. Permitted and Restricted Uses: Strategic Partner shall only use the PACKAGING CELLS and PACKAGING CELL KNOW HOW to (1) to conduct authorized studies of or other tasks relating to the PACKAGING CELLS solely for use by Vascular Biogenics and/or (2) to use this PACKAGING CELLS and PACKAGING CELL KNOW HOW to develop processes and perform other tasks for the manufacturing and making of, and to manufacture and make, PACKAGING CELLS and PRODUCT (as defined in the License) of Vascular Biogenics. Strategic Partner shall not modify, alter, change and/or reconstruct the PER.C6® CELLS, other than as otherwise permitted under the License.

 

 29
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

3. Ownership of results and materials: Subject to the terms and conditions agreed between Vascular Biogenics and Crucell in the License, all rights to any materials, data and any physical, chemical, or biological results (hereinafter referred to collectively as “RESULTS”) generated under the Alliance will vest in Vascular Biogenics or its nominee (which can include Strategic Partner if so agreed pursuant to the Alliance). If during the course and performance of the Alliance, one or more employees of Strategic Partner conceive or reduce to practice one or more inventions directly resulting from the Alliance, Strategic Partner agrees that all right, title and interest in and to all such inventions, shall vest in Vascular Biogenics or its nominee (which can include Strategic Partner if so agreed pursuant to the Alliance). Without derogating from the foregoing, to the extent certain RESULTS, including inventions and patent applications and patents emanating therefrom are subject to a license grant-back to CRUCELL under the License, Vascular Biogenics and/or the Strategic Partner, as applicable, will effect such grant-back. Strategic Partner shall promptly disclose such inventions to Vascular Biogenics, and if requested by Vascular Biogenics, shall at Vascular Biogenics’ cost and expense, diligently cooperate with Vascular Biogenics in the preparation of patent applications covering such inventions, prosecution of such applications and any other acts necessary for the protection of rights to such inventions, including, but not limited to the execution of documents such as declarations and assignments to perfect Vascular Biogenics’ rights in and to such inventions. Strategic Partner will refrain from any and all acts that may jeopardize the patentability of the invention in any jurisdiction.
   
4. Strategic Partner Control and Legal Obligations: To the extent Vascular Biogenics so agrees, Strategic Partner shall at all times maintain control over the PACKAGING CELLS and comply with all applicable laws, regulations and guidelines related to the PACKAGING CELLS (hereinafter collectively referred to as “the Rules”). Strategic Partner will not, unless Crucell and Vascular Biogenics will have given prior written approval on conditions it deems fit, release, transfer or distribute the PACKAGING CELLS to any party other than Vascular Biogenics and its authorized employees.
   
5. Reporting: All RESULTS obtained from the screening, testing or use of PACKAGING CELLS by Strategic Partner will be reported, under the confidentiality terms of Section 7, to Vascular Biogenics without delay.
   
6. Termination: After the termination or expiration of the Alliance, Strategic Partner shall transfer to Vascular Biogenics all remaining PACKAGING CELLS, derivatives and any substances obtained from the Alliance and confirm such in writing to the other Parties, or shall - at the request of Vascular Biogenics -diligently destroy the PACKAGING CELLS, derivatives and any substances derived there from in accordance with the Rules referred to in Section 4, and confirm such in writing to the other Parties. Upon completion of review of Crucell’s and Vascular Biogenics’ INFORMATION by Strategic Partner, upon the request of Crucell or in the absence of further agreement between Vascular Biogenics and Strategic Partner, Strategic Partner shall return to Vascular Biogenics all the provided INFORMATION, and any copies thereof in its possession, promptly by registered mail, certified mail, or courier service, for example, Federal Express, which retains record of the mailing, except that Strategic Partner may retain one copy of such INFORMATION for the sole purpose of determining any continuing legal obligations to Crucell and Vascular Biogenics u
   
7. Confidentiality Obligations:

 

  7.1. Strategic Partner shall treat all RESULTS and INFORMATION as confidential and shall not itself use, except for the purposes of the Alliance, or disclose to any fourth party any of such RESULTS and INFORMATION, except as to any of such RESULTS and INFORMATION which Strategic Partner can establish:

 

 30
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

  (a) at the time of disclosure is in the public domain;
     
  (b) after disclosure becomes part of the public domain by publication or otherwise, except by breach of this Agreement by Strategic Partner or breach by any other party under an agreement of confidentiality to Crucell or Vascular Biogenics;
     
  (c) by written records was in its possession at the time of disclosure by Crucell or Vascular Biogenics and was not acquired directly or indirectly from Crucell, Vascular Biogenics or from any other party under an agreement of confidentiality to Crucell or Vascular Biogenics;
     
  (d) Strategic Partner receives from a fourth party legally in a position to provide Strategic Partner with the INFORMATION or RESULTS, provided, however, that such was not obtained by said fourth party directly or indirectly from Crucell or Vascular Biogenics under an obligation of secrecy;
     
  (e) is excepted by prior written approval of Crucell and Vascular Biogenics in the case of INFORMATION or RESULTS in the case of Vascular Biogenics;
     
  (f) is required by law to be disclosed; or
     
  (g) is independently developed by Strategic Partner without reference to the INFORMATION or RESULTS as evidenced by records, however maintained.

 

  7.2. Strategic Partner shall have the right to disclose RESULTS and INFORMATION to those directors, officers, employees and consultants of Strategic Partner to whom such disclosure is necessary for the aforesaid purposes; provided that those persons to whom such RESULTS and INFORMATION may be disclosed under this paragraph have undertaken in writing confidentiality obligations with respect to such RESULTS and INFORMATION substantially similar to those undertaken by Strategic Partner under this Agreement.
     
  7.3. Strategic Partner will take all reasonable steps, including but not limited to those steps taken to protect information, data or other tangible or intangible property of its own that it regards as proprietary or confidential, to ensure that the RESULTS and INFORMATION are not disclosed or duplicated for any unauthorized party’s use and to prevent the directors, officers, employees and consultants of Strategic Partner from violating this Agreement. Strategic Partner shall notify Crucell and Vascular Biogenics promptly of its knowledge of any unauthorized use or unauthorized disclosure of RESULTS or INFORMATION.

 

8. Title and all rights to all Crucell’s INFORMATION owned by Crucell (as determined under the License) disclosed pursuant to the Alliance remain vested in Crucell.
   
9. Nothing in this Agreement is to be construed as a license to Strategic Partner to utilize Crucell’s know-how, trademarks, or tradenames, except as provided in this Agreement, in any way whatsoever or under any patent or patent application owned by Crucell, unless a separate written license agreement is executed. Any modification to this Agreement shall be in writing.
   
10. Use of Names: None of the parties will use the name of another party hereto in relation to this Agreement in any advertising or other form of publicity, without the prior written approval of such party.
   
11. Limited Warranty: Except as otherwise provided herein, Crucell and Vascular Biogenics make no representation with regard to purity or biological activity of PACKAGING CELLS provided.
   
12. Indemnification: Crucell shall not be liable for any claim or damage arising from or in connection with Strategic Partner’s use, handling or storage of PACKAGING CELLS and Strategic Partner and Vascular Biogenics shall hold harmless and indemnify Crucell for any such claim or damage, unless such claim or damage arises from the negligence or wrong-doing of Crucell.
   
13. Each party warrants that it is permitted to enter into this Agreement and that the terms of this Agreement are not inconsistent with other contractual obligations it may have.

 

 31
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

14. Notwithstanding the terms of this Agreement, no party to this Agreement shall be obligated to enter into any further agreement with the other.
   
15. This Agreement is binding upon the parties hereto and their successors in business, but is not otherwise assignable by Strategic Partner other than in connection with a merger, consolidation or sale of all or substantially all assets related to the subject matter of this Agreement.
   
16. Effective Date, Termination Date and Survival: This Agreement will be effective on ....................... and will terminate upon the earlier of (i) termination of the License or (ii) termination of Alliance. Sections 3, 5, 6, 7, 8, 10, 11, 12, 14,16, 18, 19 and 20 will survive any termination of this Agreement.
   
17. Except as otherwise set forth herein, this Agreement may not be modified, assigned or transferred in whole or in part by Strategic Partner, unless Crucell will have given prior written approval on conditions it reasonably deems fit.
   
18. Strategic Partner agrees that its obligations set forth in Sections 2, 4 and 7 are necessary and reasonable to protect Crucell and expressly agrees that monetary damages would be inadequate to compensate Crucell for any breach of any covenant or agreement set forth in Sections 2, 4 or 7. Strategic Partner agrees and acknowledges that any such violation or threatened violation may cause irreparable injury to Crucell and that in addition to any other remedies that may be available, in law, in equity or otherwise, Crucell shall be entitled to seek injunctive relief against any threatened breach of this Agreement or the continuation of any such breach, without the necessity of proving actual damages.
   
19. This Agreement shall be exclusively governed by and construed in accordance with the laws of the Netherlands. All disputes arising out of or in relation to this Agreement shall, to the exclusion of all others, be referred exclusively to the competent Dutch Courts, and the Parties agree that judgments of the competent Dutch Court are enforceable in any court having jurisdiction over the Parties. In the event of a dispute between the parties regarding this Agreement, the parties shall first attempt to resolve their dispute through amicable discussion.
   
20. In case of conflict between the License and this Agreement, the provisions of the License shall prevail, except with respect to Strategic Partner in which case this Agreement shall prevail.

 

 32
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

IN WITNESS WHEREOF, Strategic Partner, Vascular Biogenics and Crucell have executed this Agreement by their respective, duly authorized, representatives as of the date hereinafter written:

 

Crucell Holland B.V.   Vascular Biogenics Ltd.
     
By: _____________________________________   By: _____________________________________
Name:   Name:
Function:   Function:
     
Strategic Partner    
     
By: _____________________________________   By: _____________________________________
Name:   Name:
Function:   Function:

 

 33
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT A

 

LICENSE AGREEMENT

 

 34
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 2.4.1 - FORM OF MATERIAL TRANSFER AGREEMENT FOR A CONTRACTOR

 

 35
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

MATERIAL TRANSFER AND CONFIDENTIALITY AGREEMENT

 

This Material Transfer and Confidentiality Agreement (“Agreement”) is by and between

 

Crucell Holland B.V., a Dutch company with offices located at Archimedesweg 4, 2333 CN Leiden, the Netherlands, hereinafter referred to as “Crucell”; and

 

Vascular Biogenics Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter referred to as “Vascular Biogenics”), and

 

[X], a company with offices located at ..............., hereinafter referred to as “Contractor”.

 

(hereinafter individually referred to as “Party” and collectively as “Parties”)

 

WHEREAS Crucell is the owner of a proprietary PER.C6® cell line (hereinafter referred to as “PER.C6® CELLS”), and of related proprietary and confidential information and patent rights (“PER.C6® CELL KNOW-HOW”);

 

WHEREAS Crucell and Vascular Biogenics have signed a commercial license agreement that employs PER.C6® CELLS and PER.C6® CELLS modified by incorporating technology of VBL (collectively with PER.C6® CELLS, “PACKAGING CELLS”) to manufacture, use and develop a pharmaceutical products in certain fields, effective as of April_, 2011 (the “License”);

 

WHEREAS under Vascular Biogenics’ rights under Section 2.4 of the License, Vascular Biogenics wishes Contractor to perform certain work described in Attachment I, hereinafter referred to as the “Statement of Work”, using the PACKAGING CELLS and related proprietary and confidential information (“INFORMATION”), including, without limitation, related know-how (“PACKAGING CELL KNOW HOW”) on the condition that Contractor enter into this Agreement with Vascular Biogenics and Crucell;

 

WHEREAS Crucell is willing to make available the PER.C6® CELL KNOW-HOW to Contractor for the performance of the Statement of Work;

 

WHEREAS the Parties wish to make arrangements with respect to the use by Contractor of the PACKAGING CELLS and of the results of the Statement of Work performed thereon.

 

NOW THEREFORE, the Parties hereto, intending to be legally bound, agree as follows:

 

1. Supply of Know How: Crucell agrees to provide and consents to Vascular Biogenics’s providing, the PACKAGING CELLS and the INFORMATION to Contractor upon the execution of this Agreement; solely for use under the Statement of Work. If Crucell is requested to deliver PER.C6® CELLS and PER.C6® CELLS KNOW-HOW to Contractor, Crucell shall ship the PER.C6® CELLS and PER.C6® CELLS KNOW-HOW to Contractor at Vascular Biogenics’s expense.
   
2. Permitted and Restricted Uses: Contractor shall only use the PACKAGING CELLS and PACKAGING CELL KNOW HOW to (1) to conduct authorized studies of or other tasks relating to the PACKAGING CELLS solely for use by Vascular Biogenics and/or (2) to use this PACKAGING CELLS and PACKAGING CELL KNOW HOW to develop processes and perform other tasks for the manufacturing and making of, and to manufacture and make, PACKAGING CELLS and products of Vascular Biogenics. Contractor shall not modify, alter, change and/or reconstruct the PER.C6® CELLS, other than as further described in the Statement of Work.

 

 36
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Material Transfer Agreement: PER.C6® Cell Line
Crucell Holland – Contractor – Vascular Biogenics
Page 2 of 3

 

3. Ownership of results and materials: Subject to the terms and conditions agreed between Vascular Biogenics and Crucell in the License, all rights to any materials, data and any physical, chemical, or biological results (hereinafter referred to collectively as “RESULTS”) generated under the Statement of Work will vest in Vascular Biogenics. If during the course and performance of the Statement of Work, one or more employees of Contractor conceive or reduce to practice one or more inventions directly resulting from the Statement of Work, Contractor agrees that all right, title and interest in and to all such inventions, shall vest in Vascular Biogenics or its nominee. Without derogating from the foregoing, to the extent certain RESULTS, including inventions and patent applications and patents emanating therefrom are subject to a license grant-back to Crucell under the License, Vascular Biogenics will effect such grant-back. Contractor shall promptly disclose such inventions to Vascular Biogenics, and if requested by Vascular Biogenics, shall at Vascular Biogenics’s cost and expense, diligently cooperate with Vascular Biogenics in the preparation of patent applications covering such inventions, prosecution of such applications and any other acts necessary for the protection of rights to such inventions, including, but not limited to, the execution of documents such as declarations and assignments to perfect Vascular Biogenics’s rights in and to such inventions. Contractor will refrain from any and all acts that may jeopardize the patentability of the invention in any jurisdiction.
   
4. Contractor Control and Legal Obligations: Contractor shall at all times maintain control over the PACKAGING CELLS and comply with all applicable laws, regulations and guidelines related to the PACKAGING CELLS (hereinafter collectively referred to as “the Rules”). Contractor will not, unless Crucell and Vascular Biogenics will have given prior written approval on conditions it deems fit, release, transfer or distribute the PACKAGING CELLS to any party other than Vascular Biogenics and its authorized employees.
   
5. Reporting; All RESULTS obtained from the screening, testing or use of PACKAGING CELLS by Contractor will be reported, under the confidentiality terms of Section 7, to Vascular Biogenics without delay.
   
6. Termination: After the termination or expiration of this Agreement, Contractor shall transfer to Vascular Biogenics all remaining PACKAGING CELLS, derivatives and any substances obtained from the Statement of Work and confirm such in writing to the other Parties, or shall -at the request of Vascular Biogenics - diligently destroy the PACKAGING CELLS, derivatives and any substances derived there from in accordance with the Rules referred to in Section 4, and confirm such in writing to the other Parties. Upon completion of review of Crucell’s and Vascular Biogenics’ INFORMATION by Contractor, upon the request of Crucell or in the absence of further agreement between Vascular Biogenics and Contractor, Contractor shall return to Vascular Biogenics all the provided INFORMATION, and any copies thereof in its possession, promptly by registered mail, certified mail, or courier service, for example, Federal Express, which retains record of the mailing, except that Contractor may retain one copy of such INFORMATION for the sole purpose of determining any continuing legal obligations to Crucell and Vascular Biogenics.
   
7. Confidentiality Obligations:

 

  7.1. Contractor shall treat ail RESULTS and INFORMATION as confidential and shall not itself use, except for the purposes of this Agreement, or disclose to any fourth party any of such RESULTS and INFORMATION, except as to any of such RESULTS and INFORMATION which Contractor can establish:

 

  (a) at the time of disclosure is in the public domain;
     
  (b) after disclosure becomes part of the public domain by publication or otherwise, except by breach of this Agreement by Contractor or breach by any other party under an agreement of confidentiality to Crucell or Vascular Biogenics;
     
  (c) by written records was in its possession at the time of disclosure by Crucell or Vascular Biogenics and was not acquired directly or indirectly from Crucell, Vascular Biogenics or from any other party under an agreement of confidentiality to Crucell or Vascular Biogenics;

 

 37
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Material Transfer Agreement: PER.C6® Cell Line
Crucell Holland – Contractor – Vascular Biogenics
Page 2 of 3

 

  (d) Contractor receives from a fourth party legally in a position to provide Contractor with the INFORMATION or RESULTS, provided, however, that such was not obtained by said fourth party directly or indirectly from Crucell or Vascular Biogenics under an obligation of secrecy;
     
  (e) is excepted by prior written approval of Crucell and Vascular Biogenics in the case of INFORMATION or RESULTS in the case of Vascular Biogenics;
     
  (f) as required by law to be disclosed; or
     
  (g) is independently developed by Contractor without reference to the INFORMATION or RESULTS as evidenced by records, however maintained.

 

  7.2. Contractor shall have the right to disclose RESULTS and INFORMATION to those directors, officers, employees and consultants of Contractor to whom such disclosure is necessary for the aforesaid purposes; provided that those persons to whom such RESULTS and INFORMATION may be disclosed under this paragraph have undertaken in writing confidentiality obligations with respect to such RESULTS and INFORMATION substantially similar to those undertaken by Contractor under this Agreement.
     
  7.3. Contractor will take all reasonable steps, including but not limited to those steps taken to protect information, data or other tangible or intangible property of its own that it regards as proprietary or confidential, to ensure that the RESULTS and INFORMATION are not disclosed or duplicated for any unauthorized party’s use and to prevent the directors, officers, employees and consultants of Contractor from violating this Agreement. Contractor shall notify Crucell and Vascular Biogenics promptly of its knowledge of any unauthorized use or unauthorized disclosure of RESULTS or INFORMATION.

 

8. Title and all rights to all Crucell’s INFORMATION owned by Crucell (as determined under the License) disclosed under this Agreement remain vested in Crucell.
   
9. Nothing in this Agreement is to be construed as a license to Contractor to utilize Crucell’s know-how, trademarks, or tradenames, except as provided in this Agreement, in any way whatsoever or under any patent or patent application owned by Crucell, unless a separate written license agreement is executed. Any modification to this Agreement shall be in writing.
   
10. Use of Names: None of the parties will use the name of another party hereto in relation to this Agreement in any advertising or other form of publicity, without the prior written approval of such party.
   
11. Limited Warranty: Except as otherwise provided herein, Crucell and Vascular Biogenics make no representation with regard to purity or biological activity of PACKAGING CELLS provided.
   
12. Indemnification: Crucell shall not be liable for any claim or damage arising from or in connection with Contractor’s use, handling or storage of PACKAGING CELLS and Contractor and Vascular Biogenics shall hold harmless and indemnify Crucell for any such claim or damage, unless such claim or damage arises from the negligence or wrong-doing of Crucell. Vascular Biogenics shall hold harmless and indemnify Contractor for any such claim or damage, unless such claim or damage arises from the negligence or wrong-doing of Vascular Biogenics.
   
13. Each party warrants that it is permitted to enter into this Agreement and that the terms of this Agreement are not inconsistent with other contractual obligations it may have.
   
14. Notwithstanding the terms of this Agreement, no party to this Agreement shall be obligated to enter into any further agreement with the other.

 

 38
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Material Transfer Agreement: PER.C6® Cell Line
Crucell Holland – Contractor – Vascular Biogenics
Page 2 of 3

 

15. This Agreement is binding upon the parties hereto and their successors in business, but is not otherwise assignable by Contractor other than in connection with a merger, consolidation or sale of all or substantially all assets related to the subject matter of this Agreement.
   
16. Effective Date, Termination Date and Survival: This Agreement will be effective on ....................... and will terminate after the earlier of (i) the completion of the Statement of Work described in Attachment I, (ii) 60 months after the effective date or (ii) upon termination of the License. Sections 3, 5, 6, 7, 8, 10, 11, 12, 14, 16, 18, 19 and 20 will survive any termination of this Agreement.
   
17. Except as otherwise set forth herein, this Agreement may not be modified, assigned or transferred in whole or in part by Contractor, unless Crucell will have given prior written approval on conditions it reasonably deems fit.
   
18. Contractor agrees that its obligations set forth in Sections 2, 4 and 7 are necessary and reasonable to protect Crucell and expressly agrees that monetary damages would be inadequate to compensate Crucell for any breach of any covenant or agreement set forth in Sections 2, 4 or 7. Contractor agrees and acknowledges that any such violation or threatened violation may cause irreparable injury to Crucell and that in addition to any other remedies that may be available, in law, in equity or otherwise, Crucell shall be entitled to seek injunctive relief against any threatened breach of this Agreement or the continuation of any such breach, without the necessity of proving actual damages.
   
19. This Agreement shall be exclusively governed by and construed in accordance with the laws of the Netherlands. All disputes arising out of or in relation to this Agreement shall, to the exclusion of all others, be referred exclusively to the competent Dutch Courts, and the Parties agree that judgments of the competent Dutch Court are enforceable in any court having jurisdiction over the Parties. In the event of a dispute between the parties regarding this Agreement, the parties shall first attempt to resolve their dispute through amicable discussion.
   
20. In case of conflict between the License and this Agreement, the provisions of the License shall prevail, except with respect to Contractor in which case this Agreement shall prevail.

 

IN WITNESS WHEREOF, Contractor, Vascular Biogenics and Crucell have executed this Agreement by their respective, duly authorized, representatives as of the date hereinafter written:

 

Crucell Holland B.V.
For and on behalf of Crucell N.V.
  Vascular Biogenics Ltd.
     
By: _____________________________________   By: _____________________________________
Name:   Name:
Function:   Function:
     
Contractor    
     
By: _____________________________________ By: _____________________________________
Name:   Name:
Function:   Function:

 

 39
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Attachment I: Statement of Work to which the use of the MATERIAL is to be limited

 

Contractor may only use MATERIAL and INFORMATION for

 

 40
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 2.4.2 - PRE-APPROVED THIRD PARTY CONTRACTORS

 

 41
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 3.5.1- QUARTERLY REPORTING FORM

 

To: CRUCELL HOLLAND B.V.

Archimedesweg 4

P.O. Box 2048

2301 CA Leiden

THE NETHERLANDS

Attn. Business Development

FAX: +31-71-5199800

 

From: (Please fill in COMPANY name and address)

 

 

 

 

  

Date: ___________________

 

Subject: QUARTERLY REPORT LICENSE AGREEMENT

 

  1) Period covered by the report

 

 

 

  2) General culturing

 

  A short description on general cell culture activities.
  Have you encountered problems culturing the PER.C6® cell line?
  Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW FILE?

 

 

 

  3) VECTOR production

 

  Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS?
  Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE?

 

 

 

  4) Interactions with regulatory authorities

 

  In the past three months, were there any communications with regulatory authorities that were NOT subject to Section 3,4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and the outcome of these discussions. Please provide copies of the communication.
  What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes? Please provide reason, nature and outcome of the tests.

 

 

 

 42
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

EXHIBIT 3.5.2. - ANNUAL REPORTING FORM

 

To: CRUCELL HOLLAND B.V.

Archimedesweg 4

2048

2301 CA Leiden

THE NETHERLANDS

Attn. Business Development

FAX: +31-71-5199800

 

From: (Please fill in COMPANY name and address)

 

 

 

 

 

Subject: ANNUAL REPORT LICENSE AGREEMENT

 

  1) Period covered by the report

 

 

 

  2) General culturing

 

  A short description on general cell culture activities.
  Media used.
  Cell banks prepared.
  General performance; cell growth, viabilities, doubling times.
  Scale and scale-up data.
  Systems used (Shake-flasks, Roller bottles, Bioreactors, Wave bags).
  Have you encountered problems culturing the PER.C6® cell line?

 

 

Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW files?

 

 

 

  3) VECTOR production

 

  Number and type of vectors produced in the PER.C6® cell line.
  Yields reached per produced VECTOR.
  Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS?
  Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE?
  Code(s) for tracking the individual new PRODUCT in future reports.

 

 

 

  4) Third party activities

 

  Have you performed CMO activities for THIRD PARTIES using the PER.C6® cell line or worked with the PER.C6® cell line in collaborations programs with THIRD PARTIES? If yes, please state the name of the company/companies and a short description of the project(s).
  Has a CMO performed any activities with the PER.C6® cell line? If yes, please state the name of the company/companies and a short description of the project(s).

 

 

 

  5) Interactions with regulatory authorities / Clinical activities

 

  What pre-IND meetings and IND filings have taken place for products produced on PER.C6®? For which products? What was the outcome (related to PER.C6®) of those meetings?
  Were there any communications with regulatory authorities that were NOT subject to Section 3.4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and the outcome of these discussions. Please provide copies of the communication.
  What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes. Please provide reason, nature and outcome of the tests.
  Was clinical material produced using the PER.C6® cell line?

 

 43
 
Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 

 

 

Exhibit 12.1

 

I, Dror Harats, certify that:

 

1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F of Vascular Biogenics Ltd.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Date: October 11, 2017

 

/s/ Dror Harats  

Dror Harats

 
Chief Executive Officer  

 

 

 

 

Exhibit 12.2

 

I, Amos Ron, certify that:

 

1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F of Vascular Biogenics Ltd.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Date: October 11, 2017

 

/s/ Amos Ron  

Amos Ron

 
Chief Financial Officer